Intellia Therapeutics (NASDAQ:NTLA) Trading Down 8.2% After Analyst Downgrade

Intellia Therapeutics, Inc. (NASDAQ:NTLA)’s stock price fell 8.2% during mid-day trading on Thursday after HC Wainwright lowered their price target on the stock from $30.00 to $25.00. HC Wainwright currently has a buy rating on the stock. Intellia Therapeutics traded as low as $13.09 and last traded at $13.1140. 7,207,754 shares changed hands during trading, an increase of 35% from the average session volume of 5,327,713 shares. The stock had previously closed at $14.28.

Several other research analysts also recently weighed in on the company. KeyCorp set a $25.00 price target on Intellia Therapeutics in a research note on Wednesday, January 28th. JonesTrading upgraded Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $29.00 price target for the company in a research note on Wednesday, March 4th. Royal Bank Of Canada upped their price target on Intellia Therapeutics from $9.00 to $15.00 and gave the stock a “sector perform” rating in a research note on Tuesday, March 3rd. Morgan Stanley upped their price target on Intellia Therapeutics from $11.00 to $15.00 and gave the stock an “equal weight” rating in a research note on Monday, April 27th. Finally, Canaccord Genuity Group dropped their price target on Intellia Therapeutics from $58.00 to $49.00 and set a “buy” rating for the company in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $20.25.

Key Intellia Therapeutics News

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on Intellia Therapeutics and maintained a $25 price target, implying substantial upside versus the current share price. The firm also reiterated estimates that reflect continued losses but a path toward improvement. Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $25.00 by Analysts at HC Wainwright
• Neutral Sentiment: HC Wainwright’s forecast updates for Q1 2027, Q2 2027, and FY2027 were broadly in line with the company’s loss-making profile, suggesting analysts still expect Intellia to burn cash but do not see a major near-term fundamental surprise.
• Neutral Sentiment: Wedbush reaffirmed a Hold/Neutral view on NTLA, reinforcing the market’s wait-and-see stance ahead of key clinical and commercial milestones. Wedbush Remains a Hold on Intellia Therapeutics (NTLA)
• Negative Sentiment: HC Wainwright cut its price target from $30 to $25, which can weigh on sentiment even though the stock still has implied upside from that target.
• Negative Sentiment: Brookline Capital Markets lowered earnings estimates for multiple periods, including Q3 2026, Q4 2026, and FY2026, signaling softer expected profitability and adding to the cautious analyst backdrop.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Comerica Bank boosted its position in shares of Intellia Therapeutics by 45.8% during the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after acquiring an additional 901 shares during the last quarter. Headlands Technologies LLC purchased a new stake in Intellia Therapeutics during the 2nd quarter valued at $26,000. Caitong International Asset Management Co. Ltd purchased a new stake in Intellia Therapeutics during the 3rd quarter valued at $30,000. Advisory Services Network LLC purchased a new stake in Intellia Therapeutics during the 3rd quarter valued at $33,000. Finally, Spire Wealth Management purchased a new stake in Intellia Therapeutics during the 4th quarter valued at $37,000. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Stock Performance

The company has a fifty day moving average of $13.65 and a two-hundred day moving average of $12.07. The company has a market cap of $1.81 billion, a PE ratio of -3.69 and a beta of 1.93.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.11. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.The company had revenue of $15.05 million for the quarter, compared to analyst estimates of $13.81 million. During the same quarter in the prior year, the firm posted ($1.10) EPS. On average, equities analysts forecast that Intellia Therapeutics, Inc. will post -3.38 EPS for the current year.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical?stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease?causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.